Wave Life Sciences (WVE) Proxy filing summary

Executive summary

• A restructuring will redomicile the parent company from Singapore to Delaware, USA, via a scheme of arrangement, subject to shareholder and Singapore High Court approval.

• Shareholders will exchange each Singapore ordinary share for one Delaware common share; the new parent will continue to operate as before and remain listed on Nasdaq under the same symbol.

• The move aims to streamline organizational, statutory, and regulatory structures, reduce compliance costs, and better align the parent company's domicile with its operations and personnel, most of which are already in the US.

• The transaction is expected to be tax-free for US shareholders and is anticipated to take effect in mid-2026, pending approvals.

• Forward-looking statements highlight risks such as obtaining necessary approvals, realizing expected benefits, regulatory delays, and changes in tax laws.

Voting matters and shareholder proposals

• Shareholders must approve the redomiciliation at a special meeting convened by court order; approval is a condition precedent for the transaction.

• The definitive proxy statement will be mailed to shareholders and will contain detailed information about the redomiciliation.

Board of directors and corporate governance

• The directors and officers of the Singapore entity will become the directors and officers of the Delaware entity immediately following the effective time, maintaining continuity.